Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) had its target price cut by UBS AG from $19.00 to $15.00 in a report published on Thursday morning. They currently have a buy rating on the biopharmaceutical company’s stock.
A number of other equities research analysts also recently issued reports on the stock. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, October 3rd. Mizuho downgraded shares of Sucampo Pharmaceuticals from a buy rating to a neutral rating and reduced their price target for the company from $14.00 to $12.00 in a research note on Tuesday, October 3rd. Leerink Swann assumed coverage on shares of Sucampo Pharmaceuticals in a research note on Monday, August 21st. They issued an outperform rating and a $15.00 price target on the stock. Maxim Group restated a buy rating and issued a $23.00 price target (up from $21.00) on shares of Sucampo Pharmaceuticals in a research note on Tuesday, August 8th. Finally, BidaskClub downgraded shares of Sucampo Pharmaceuticals from a buy rating to a hold rating in a research note on Saturday, August 5th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $17.29.
Sucampo Pharmaceuticals (NASDAQ SCMP) traded down 1.92% during trading on Thursday, reaching $10.20. 513,824 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $11.63 and its 200 day moving average price is $10.72. The firm’s market cap is $472.51 million. Sucampo Pharmaceuticals has a 52-week low of $9.30 and a 52-week high of $17.55.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.06. The firm had revenue of $59.90 million for the quarter, compared to the consensus estimate of $56.44 million. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The business’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.24 earnings per share. Equities research analysts anticipate that Sucampo Pharmaceuticals will post $1.01 EPS for the current fiscal year.
In other Sucampo Pharmaceuticals news, insider Jones W. Bryan bought 4,700 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The shares were acquired at an average cost of $10.60 per share, for a total transaction of $49,820.00. Following the transaction, the insider now directly owns 4,700 shares in the company, valued at $49,820. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of Sucampo Pharmaceuticals stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $12.00, for a total transaction of $12,000,000.00. The disclosure for this sale can be found here. Company insiders own 4.13% of the company’s stock.
Large investors have recently bought and sold shares of the stock. AlphaMark Advisors LLC boosted its position in Sucampo Pharmaceuticals by 25.4% during the 2nd quarter. AlphaMark Advisors LLC now owns 98,400 shares of the biopharmaceutical company’s stock worth $1,033,000 after buying an additional 19,900 shares during the period. Bank of New York Mellon Corp boosted its position in Sucampo Pharmaceuticals by 107.3% during the 1st quarter. Bank of New York Mellon Corp now owns 367,691 shares of the biopharmaceutical company’s stock worth $4,044,000 after buying an additional 190,292 shares during the period. Texas Permanent School Fund boosted its position in Sucampo Pharmaceuticals by 2.2% during the 2nd quarter. Texas Permanent School Fund now owns 18,319 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 398 shares during the period. State of Tennessee Treasury Department acquired a new stake in Sucampo Pharmaceuticals during the 1st quarter worth approximately $258,000. Finally, Vanguard Group Inc. boosted its position in Sucampo Pharmaceuticals by 48.9% during the 1st quarter. Vanguard Group Inc. now owns 1,456,787 shares of the biopharmaceutical company’s stock worth $16,024,000 after buying an additional 478,226 shares during the period. Institutional investors and hedge funds own 55.46% of the company’s stock.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.